This site uses cookies. By using this site you agree to receiving cookies. View Policy.

171%

Virus and rare disease research has never been more prominent. 42Genetics' software provides a fast, low-cost solution to the creation and storage of large DNA genomic data files, facilitating academia, pharma and medical professionals to carry out ground-breaking research.

  • Software patented, registered in the Netherlands with academic validation
  • Genomics industry worth $18.85bn in 2019, expected to grow to $82.6bn by 2027.
  • Undertaking a pioneering processing project with Cambridge University
  • Ever increasing quantum of Genomic data to be analysed by industry

Idea

42 Genetic's Investment Video!

1 in 17 people (7% of the population) will be affected by a rare disease at some point in their lives. This is about 3 million people in the UK. 80% of rare diseases include cancers, and some other well-known conditions such as cystic fibrosis and Huntington’s disease, have a genetic component.

42Genetics is on a mission to unlock genomic data for the world’s health organizations by providing data-driven solutions for diagnostics and discovery at scale. We are in negotiations with a life-science organization to progress precision medicine programs, enable high throughput diagnostics and accelerate the pace of research.

A digitised human genome is 500GB in size when output from a sequencer and this makes it difficult to transfer through the Cloud and very costly to store, especially when working with large population groups. 42Genetics reduces the footprint to less than 5GB thus facilitating speed and making research more affordable. The Genomics industry was worth $18.85bn in 2019 and is projected to grow to $82.6bn by 2027.

The team have significant experience in building genetic software, and in February 2020, we completed a validation project with Cambridge University, hosting and processing 15,000 whole genomes and achieving a publication in Nature journal along with NIHR and Genomics England.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

To see the rest of the 42 Genetics pitch, join now. It's free, quick and easy.

Due to financial regulations, you need to join our community to view the full investment opportunity.

Join

Already registered?
Log in

Risk warning

Investments of this nature carry risks to your capital, including illiquidity, lack of dividends and dilution. Balance risk with a diversified portfolio. Read more. Approved as a financial promotion by Crowdcube Capital Limited, which is authorised and regulated by the Financial Conduct Authority.

Investment opportunities are not offers to the public and investors must be eligible Crowdcube members. Further restrictions and Crowdcube's limitation of liability are set out in the Investor Terms and Conditions. Please seek independent advice as required as Crowdcube does not give investment or tax advice.

42 Genetics has been given advance assurance by HMRC that the proposed share issue is likely to qualify for Enterprise Investment Scheme (EIS) tax relief.

Tax relief is available to individuals only, with income tax relief currently set at 30 per cent of the cost of the shares for the tax year in which the investment was made. The tax reliefs can also reduce your Capital Gains Tax bill. Read More.

Availability of tax relief depends on your individual and the company’s ongoing circumstances and applicable law.